Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Vogl

Showing results (251-260 of 342) with videos related to

Pageof 35
Sort By:
Blood|December 4, 2024
Targeted interferon therapy with modakafusp alfa for relapsed or refractory multiple myelomaDan T Vogl, Shebli Atrash, Sarah A Holstein, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 6, 2017
Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple MyelomaDan T Vogl, Noopur Raje, Sundar Jagannath, et al.
Bone Marrow Transplantation|April 28, 2010
Stem cell collection in patients with multiple myeloma: impact of induction therapy and mobilization regimenA Nazha, R Cook, D T Vogl, et al.
Leukemia|February 15, 2019
RUNX proteins desensitize multiple myeloma to lenalidomide via protecting IKZFs from degradationNan Zhou, Alvaro Gutierrez-Uzquiza, Xiang Yu Zheng, et al.
Haematologica|February 6, 2025
Non-tuberculous mycobacterial infections following teclistamab in multiple myelomaMatthew Ho, Luca Paruzzo, Janna Minehart, et al.
Bone Marrow Transplantation|October 14, 2008
Second auto-SCT is safe and effective salvage therapy for relapsed multiple myelomaR L Olin, D T Vogl, D L Porter, et al.
Annals of the Rheumatic Diseases|December 25, 2015
Elevated calprotectin levels reveal bowel inflammation in spondyloarthritisH Cypers, G Varkas, S Beeckman, et al.
Arthritis and Rheumatism|October 1, 2009
Scavenger receptor class A type I/II determines matrix metalloproteinase-mediated cartilage destruction and chondrocyte death in antigen-induced arthritisP L E M van Lent, W Hofkens, A B Blom, et al.
Blood Advances|February 24, 2026
Outcomes of radiation integrated with T-cell-engaging bispecific antibodies in relapsed/refractory multiple myelomaHeta Patel, Harper Hubbeling, Kyle Yu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 12, 2025
A Phase I Clinical Study and In Vivo Findings with PT-112, a Novel Immunogenic Cell Death-Inducing Small Molecule, in Relapsed or Refractory Multiple MyelomaTaxiarchis Kourelis, Sikander Ailawadhi, Dan T Vogl, et al.
Pageof 35

Showing results (251-260 of 342) with videos related to

Sort By:
Pageof 35
Blood|December 4, 2024
Targeted interferon therapy with modakafusp alfa for relapsed or refractory multiple myelomaDan T Vogl, Shebli Atrash, Sarah A Holstein, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 6, 2017
Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple MyelomaDan T Vogl, Noopur Raje, Sundar Jagannath, et al.
Bone Marrow Transplantation|April 28, 2010
Stem cell collection in patients with multiple myeloma: impact of induction therapy and mobilization regimenA Nazha, R Cook, D T Vogl, et al.
Leukemia|February 15, 2019
RUNX proteins desensitize multiple myeloma to lenalidomide via protecting IKZFs from degradationNan Zhou, Alvaro Gutierrez-Uzquiza, Xiang Yu Zheng, et al.
Haematologica|February 6, 2025
Non-tuberculous mycobacterial infections following teclistamab in multiple myelomaMatthew Ho, Luca Paruzzo, Janna Minehart, et al.
Bone Marrow Transplantation|October 14, 2008
Second auto-SCT is safe and effective salvage therapy for relapsed multiple myelomaR L Olin, D T Vogl, D L Porter, et al.
Annals of the Rheumatic Diseases|December 25, 2015
Elevated calprotectin levels reveal bowel inflammation in spondyloarthritisH Cypers, G Varkas, S Beeckman, et al.
Arthritis and Rheumatism|October 1, 2009
Scavenger receptor class A type I/II determines matrix metalloproteinase-mediated cartilage destruction and chondrocyte death in antigen-induced arthritisP L E M van Lent, W Hofkens, A B Blom, et al.
Blood Advances|February 24, 2026
Outcomes of radiation integrated with T-cell-engaging bispecific antibodies in relapsed/refractory multiple myelomaHeta Patel, Harper Hubbeling, Kyle Yu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 12, 2025
A Phase I Clinical Study and In Vivo Findings with PT-112, a Novel Immunogenic Cell Death-Inducing Small Molecule, in Relapsed or Refractory Multiple MyelomaTaxiarchis Kourelis, Sikander Ailawadhi, Dan T Vogl, et al.
Pageof 35